XML 68 R33.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Development and Other Agreements - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions |  | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Nov. 20, 2018 | Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 28, 2018
Development Agreements [Line Items] |  |  |  |  |  |  |
Collaborative research and development fee |  | $ 87.1 | $ 87.1 | $ 0.0 | $ 0.0 |  |
Collaborative Arrangement | Verily Life Sciences | Collaborative Arrangement, Initial Payment |  |  |  |  |  |  |
Development Agreements [Line Items] |  |  |  |  |  |  |
Initial payment on collaborative agreement | $ 250.0 |  |  |  |  |  |
Issuance of common stock in connection with acquisition, shares (in shares) | 1,840,943 |  |  |  |  |  |
Collaborative research and development fee |  | $ 87.1 |  |  |  | $ 217.7 |
Closing stock price (USD per share) |  |  |  |  |  |  | $ 118.28
Collaborative Arrangement | Verily Life Sciences | Collaborative Arrangement, Approval Milestone |  |  |  |  |  |  |
Development Agreements [Line Items] |  |  |  |  |  |  |
Potential future common stock issuable (shares) | 736,377 |  |  |  |  |  |
Collaborative Arrangement | Verily Life Sciences | Collaborative Arrangement, Milestone Payments |  |  |  |  |  |  |
Development Agreements [Line Items] |  |  |  |  |  |  |
Collaborative research and development fee |  |  |  |  | $ 3.2 |  |
Potential future common stock issuable (shares) | 1,288,660 |  |  |  |  |  |

X
- Definition Collaborative Arrangement, Upfront Fee + References No definition available. + Details
Name: | dxcm_CollaborativeArrangementUpfrontFee
Namespace Prefix: | dxcm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Research and Development Fee + References No definition available. + Details
Name: | dxcm_CollaborativeResearchAndDevelopmentFee
Namespace Prefix: | dxcm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development Agreements [Line Items] + References No definition available. + Details
Name: | dxcm_DevelopmentAgreementsLineItems
Namespace Prefix: | dxcm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential Future Common Stock Issuable, Shares, New Issues + References No definition available. + Details
Name: | dxcm_PotentialFutureCommonStockIssuableSharesNewIssues
Namespace Prefix: | dxcm_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dxcm_VerilyLifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dxcm_PaymentsUnderCollaborationAgreementsAxis=dxcm_CollaborativeArrangementInitialPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dxcm_PaymentsUnderCollaborationAgreementsAxis=dxcm_CollaborativeArrangementApprovalMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dxcm_PaymentsUnderCollaborationAgreementsAxis=dxcm_CollaborativeArrangementMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |